Sphingosine-1-phosphate receptor 1/5 modulator
Siponimod
Brand names: Mayzent
Adult dose
Dose: Days 1-5 dose-titration pack to maintenance (1 or 2mg OD per CYP2C9 genotype)
Route: PO
Frequency: OD
Clinical pearls
- Active secondary progressive MS
- CYP2C9 genotype before; first-dose ECG monitoring
Contraindications
- CYP2C9 *3/*3 genotype
- Recent MI/stroke/severe HF (≤6mo)
- Mobitz II / 3rd-degree AV block without pacemaker
- Severe hepatic impairment
- Pregnancy
Side effects
- First-dose bradycardia/AV block
- Macular oedema
- Hepatotoxicity
- Hypertension
- Infections (incl. PML)
- Reduced FEV1
Interactions
- β-blockers
- Antiarrhythmics
- Live vaccines
- CYP2C9/3A4 modulators
Monitoring
- LFTs
- FBC
- BP
- Ophthalmic
- ECG
Reference: BNF; NICE TA656; SmPC; https://bnf.nice.org.uk/drugs/siponimod/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS